IVD MEDICAL (01931) and TRANSCENTA-B (06628) signed a strategic cooperation agreement involving the tokenization of $1.5 billion in innovative drug pipeline assets.

IVD MEDICAL (01931) announced that the company and its subsidiary companies ETHK Inc. and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Transcenta Holding Limited (Transcenta Group, stock code: 06628.HK) and its subsidiary company Transcenta Oncology Inc. (US) (collectively referred to as Transcenta Group) on the potential securitization of innovative drug pipeline assets RWA tokens. Under this agreement, Transcenta Group will consolidate its six core innovative drug pipeline assets (namely TST003, TST005, TST786, TST105, TST106, and TST013) under its US entity, Transcenta Oncology Inc. (US), and cooperate with IVD MEDICAL on the potential securitization of the assets through the ETHK Global Innovation Drug Intellectual Property RWA Exchange established by the group. These assets have a total estimated value exceeding $1.5 billion, representing cutting-edge research and high technological barriers in the global oncology field. The group will provide a full-process technical solution covering digital initiation, trustworthy blockchain linking, compliant issuance, and liquidity docking for these pipeline assets. This cooperation marks the formal launch of the world's first high-value innovative drug intellectual property assets in RWA form, representing a milestone event where technology and finance are deeply integrated. This cooperation will explore the potential issuance of RWA tokens for the six innovative drug pipelines, covering various cutting-edge technology platforms such as bispecifics, trispecifics, ADCs, and fusion proteins, each pipeline having global innovative (First-in-Class) or best-in-class potential. Upon the successful completion of this cooperation, it will not only be token issuance on the blockchain but also a revolution in the traditional R&D financing and value realization model in the biopharmaceutical industry. Through RWA securitization: Lock in the R&D value of high-value pipelines in advance: Enables issuers to efficiently activate their top pipeline assets at different clinical stages, injecting innovative funds without diluting equity. Provide a new channel for global capital allocation: Provides global professional investors with a rare opportunity to transparently, compliantly, and efficiently allocate the world's leading-edge innovative drug intellectual property assets, sharing the dividends of bio-tech breakthroughs. Accelerate therapy accessibility: Accelerate the R&D process of cutting-edge therapies through innovative financing models, ultimately benefiting global patients and meeting urgent, unmet medical needs. The announcement stated that this cooperation will generate significant synergies, injecting strong momentum into the group's sustainable business growth and financial performance. The group will closely collaborate with Transcenta Group to ensure the successful implementation of this project.